What is the share price of Brawn Biotech Ltd (BRAWN) today?
The share price of BRAWN as on 27th June 2025 is ₹16.16. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Brawn Biotech Ltd (BRAWN) share?
The past returns of Brawn Biotech Ltd (BRAWN) share are- Past 1 week: -4.12%
- Past 1 month: -8.82%
- Past 3 months: -7.13%
- Past 6 months: -33.96%
- Past 1 year: -40.15%
- Past 3 years: 0.06%
- Past 5 years: -34.44%
What are the peers or stocks similar to Brawn Biotech Ltd (BRAWN)?
The peers or stocks similar to Brawn Biotech Ltd (BRAWN) include:What is the market cap of Brawn Biotech Ltd (BRAWN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Brawn Biotech Ltd (BRAWN) is ₹4.85 Cr as of 27th June 2025.What is the 52 week high and low of Brawn Biotech Ltd (BRAWN) share?
The 52-week high of Brawn Biotech Ltd (BRAWN) is ₹27.49 and the 52-week low is ₹15.46.What is the PE and PB ratio of Brawn Biotech Ltd (BRAWN) stock?
The P/E (price-to-earnings) ratio of Brawn Biotech Ltd (BRAWN) is -2.71. The P/B (price-to-book) ratio is 0.96.Which sector does Brawn Biotech Ltd (BRAWN) belong to?
Brawn Biotech Ltd (BRAWN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Brawn Biotech Ltd (BRAWN) shares?
You can directly buy Brawn Biotech Ltd (BRAWN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Brawn Biotech Ltd
BRAWN Share Price
16.160.00% (+0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
BRAWN Performance & Key Metrics
BRAWN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -2.69 | 0.96 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.01 | 6.54 | 0.84% |
BRAWN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BRAWN Company Profile
Brawn Biotech Limited is an integrated healthcare company in India, offering a wide range of pharmaceutical products including antibacterials, cardiovasculars, antifungals, and more.
SUNPHARMA
PE Ratio
36.66
36.66
1Y Return
9.77%
9.77%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.19
23.19
1Y Return
2.35%
2.35%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
19.45
19.45
1Y Return
8.85%
8.85%
Buy Reco %
55.17
55.17
TORNTPHARM
PE Ratio
57.07
57.07
1Y Return
15.48%
15.48%
Buy Reco %
72.00
72.00
ZYDUSLIFE
PE Ratio
21.83
21.83
1Y Return
7.87%
7.87%
Buy Reco %
46.43
46.43
BRAWN Forecast
BRAWN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BRAWN
BRAWN
Income
Balance Sheet
Cash Flow
Annual Normal View
BRAWN Income Statement
BRAWN Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 61.17 | 55.87 | 65.92 | 49.79 | 35.29 | 8.62 | 22.24 | 16.58 | 13.56 | 13.56 | ||||||||||
Raw Materials | 52.07 | 48.82 | 58.49 | 42.15 | 29.89 | 11.05 | 19.24 | 15.59 | 15.24 | 15.24 | ||||||||||
| Power & Fuel Cost | 0.01 | 0.03 | 0.05 | 0.05 | 0.04 | 0.02 | 0.06 | 0.08 | ||||||||||||
| Employee Cost | 1.98 | 2.98 | 3.02 | 3.08 | 2.36 | 1.80 | 1.40 | 1.40 | ||||||||||||
| Selling & Administrative Expenses | 2.16 | 1.74 | 2.29 | 2.07 | 1.50 | 1.81 | 1.55 | 1.76 | ||||||||||||
| Operating & Other expenses | 3.09 | 0.25 | 0.16 | 1.53 | 1.78 | -4.06 | 0.28 | -0.86 | ||||||||||||
EBITDA | 1.86 | 2.05 | 1.91 | 0.91 | -0.28 | -2.00 | -0.29 | -1.39 | -1.68 | -1.68 | ||||||||||
| Depreciation/Amortization | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.11 | 0.10 | 0.11 | 0.12 | ||||||||||
| PBIT | 1.83 | 2.02 | 1.88 | 0.88 | -0.31 | -2.05 | -0.40 | -1.49 | -1.79 | -1.80 | ||||||||||
| Interest & Other Items | 0.07 | 0.06 | 0.07 | 0.05 | 0.04 | 0.06 | 0.01 | 0.06 | 0.00 | — | ||||||||||
| PBT | 1.76 | 1.96 | 1.81 | 0.83 | -0.35 | -2.11 | -0.41 | -1.55 | -1.79 | -1.80 | ||||||||||
| Taxes & Other Items | 0.36 | 0.68 | 0.48 | 0.23 | 0.20 | -0.47 | 0.45 | -0.30 | 0.00 | — | ||||||||||
| Net Income | 1.40 | 1.28 | 1.33 | 0.60 | -0.55 | -1.64 | -0.86 | -1.25 | -1.79 | -1.80 | ||||||||||
| EPS | 4.67 | 4.27 | 4.43 | 2.00 | -1.83 | -5.47 | -2.87 | -4.17 | -5.87 | -6.00 | ||||||||||
| DPS | 1.50 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.32 | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
BRAWN Company Updates
BRAWN Stock Peers
BRAWN Past Performance & Peer Comparison
BRAWN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Brawn Biotech Ltd | -2.71 | 0.96 | — |
| Sun Pharmaceutical Industries Ltd | 36.66 | 5.97 | 0.96% |
| Cipla Ltd | 23.19 | 3.91 | 1.06% |
| Dr Reddy's Laboratories Ltd | 19.45 | 3.89 | 0.61% |
BRAWN Stock Price Comparison
Compare BRAWN with any stock or ETFCompare BRAWN with any stock or ETF
BRAWN
BRAWN Holdings
BRAWN Shareholdings
BRAWN Promoter Holdings Trend
BRAWN Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BRAWN Institutional Holdings Trend
BRAWN Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BRAWN Shareholding Pattern
BRAWN Shareholding Pattern
BRAWN Shareholding History
BRAWN Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing BRAWN stock
smallcases containing BRAWN stock
Looks like this stock is not in any smallcase yet.
BRAWN Events
BRAWN Events
BRAWN Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BRAWN has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
BRAWN Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BRAWN has not given any dividends in last 5 years
BRAWN Upcoming Dividends
BRAWN Upcoming Dividends
No upcoming dividends are available
BRAWN Past Dividends
BRAWN Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2018
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 12, 2018
Cash Dividend
Ex DateEx DateSep 14, 2017
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 14, 2017
BRAWN Stock News & Opinions
BRAWN Stock News & Opinions
Articles & Videos
Earnings
Brawn Biotech reports standalone net loss of Rs 0.49 crore in the March 2025 quarter
Net Loss of Brawn Biotech reported to Rs 0.49 crore in the quarter ended March 2025 as against net loss of Rs 0.34 crore during the previous quarter ended March 2024. Sales declined 34.49% to Rs 2.26 crore in the quarter ended March 2025 as against Rs 3.45 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 1.80 crore in the year ended March 2025 as against net loss of Rs 1.54 crore during the previous year ended March 2024. Sales declined 18.31% to Rs 13.47 crore in the year ended March 2025 as against Rs 16.49 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2.263.45 -34 13.4716.49 -18 OPM %-24.34-11.30 --13.21-9.28 - PBDT-0.46-0.31 -48 -1.69-1.44 -17 PBT-0.49-0.34 -44 -1.80-1.54 -17 NP-0.49-0.34 -44 -1.80-1.54 -17 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Brawn Biotech to table results
Brawn Biotech will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Brawn Biotech reports standalone net loss of Rs 0.43 crore in the December 2024 quarter
Net Loss of Brawn Biotech reported to Rs 0.43 crore in the quarter ended December 2024 as against net loss of Rs 0.61 crore during the previous quarter ended December 2023. Sales rose 35.21% to Rs 3.84 crore in the quarter ended December 2024 as against Rs 2.84 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales3.842.84 35 OPM %-10.42-20.42 - PBDT-0.40-0.58 31 PBT-0.43-0.61 30 NP-0.43-0.61 30 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Brawn Biotech to table results
Brawn Biotech will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Brawn Biotech reports standalone net loss of Rs 0.34 crore in the September 2024 quarter
Net Loss of Brawn Biotech reported to Rs 0.34 crore in the quarter ended September 2024 as against net loss of Rs 0.42 crore during the previous quarter ended September 2023. Sales rose 13.01% to Rs 3.30 crore in the quarter ended September 2024 as against Rs 2.92 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3.302.92 13 OPM %-9.39-13.36 - PBDT-0.31-0.39 21 PBT-0.34-0.42 19 NP-0.34-0.42 19 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Brawn Biotech to conduct board meeting
Brawn Biotech will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Brawn Biotech to conduct AGM
Brawn Biotech announced that the 39th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Brawn Biotech reports standalone net loss of Rs 0.53 crore in the June 2024 quarter
Net Loss of Brawn Biotech reported to Rs 0.53 crore in the quarter ended June 2024 as against net loss of Rs 0.17 crore during the previous quarter ended June 2023. Sales declined 44.31% to Rs 4.06 crore in the quarter ended June 2024 as against Rs 7.29 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales4.067.29 -44 OPM %-12.32-2.06 - PBDT-0.50-0.15 -233 PBT-0.53-0.17 -212 NP-0.53-0.17 -212 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Brawn Biotech to discuss results
Brawn Biotech will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -24.12%, vs industry avg of 9.02%
Over the last 5 years, market share decreased from 0.03% to 0%